Gene Therapy in CNS Disorder Market

Gene Therapy in CNS Disorder Market Snapshot (2023 to 2033) 

The global gene therapy in CNS disorder market is expected to garner a market value of USD 8.2 Billion in 2023 and is expected to accumulate a market value of USD 113.04 Billion by registering a CAGR of 30% in the forecast period 2023 to 2033. The market for gene therapy in CNS disorders registered a CAGR of 19% in the historical period 2018 to 2022.

The gene therapy market for CNS disorders is rapidly growing, with a focus on delivering therapeutic genes directly to the brain to treat neurological conditions. The Gene Therapy in CNS Disorder market is a segment of the healthcare industry that deals with the effective management of the condition. The Gene Therapy in CNS Disorder market offers a range of products and services for its effective management and treatments. The most common CNS disorders being targeted by gene therapy include Parkinson's disease, Alzheimer's disease, Spinal Muscular Atrophy (SMA), Huntington's disease, and ALS (Amyotrophic Lateral Sclerosis).

Data Points	Key Statistics
Expected Market Value (2023)	USD 8.2 billion
Anticipated Forecast Value (2033)	USD 113.04 billion
Projected Growth Rate (2023 to 2033)	30% CAGR

2018 to 2022 Gene Therapy in CNS Disorder Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for gene therapy in CNS disorder reflected a value of 19% during the historical period, 2018 to 2022.

During this period, the demand for gene therapy for CNS disorders increased due to the rising prevalence of these disorders, advancements in gene therapy technology, increasing awareness among healthcare providers and patients, and regulatory support. The market for Gene Therapy in CNS Disorder is gaining prominence as several companies are investing heavily in research and development of these therapies, resulting in the development of new treatment options for conditions such as Parkinson's disease, Alzheimer's disease, SMA, and ALS.

Looking ahead to the period from 2023 to 2033, the gene therapy market for CNS disorders is expected to continue growing. The increasing prevalence of CNS disorders and the rising demand for effective treatments are expected to drive demand for gene therapy in this space. Furthermore, the increasing investment in research and development of gene therapy for CNS disorders, along with the increasing regulatory support, is expected to result in the development and approval of more gene therapies for these conditions.

Overall, the gene therapy market for CNS disorders is expected to experience strong demand from 2023 to 2033, driven by several factors such as the increasing prevalence of these conditions, advancements in technology, growing awareness, and regulatory support.

In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies are creating awareness of Gene Therapy in CNS Disorder, fuelling the market growth. Thus, the market for Gene Therapy in CNS Disorder is expected to register a CAGR of 30% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Gene Therapy in the CNS Disorder Market?

Growing advancements in diagnostic and treatment options to push the market growth

The global gene therapy in CNS disorder market is primarily driven by an increased prevalence of CNS disorders such as, such as Parkinson's disease, Alzheimer's disease, and ALS, which is on the rise, which is driving the demand for effective treatments.

Up to 1 billion people, nearly one in six of the world’s population, suffer from neurological disorders, from Alzheimer and Parkinson disease, strokes, multiple sclerosis and epilepsy to migraine, brain injuries and neuroinfections, with some 6.8 million dying of the maladies each year, according to a new United Nations report.

There have been significant advancements in gene therapy technology, including the development of viral vectors that can deliver therapeutic genes to the brain more efficiently and safely.

Additionally, the growth of the Gene Therapy in CNS Disorder market is owed to ongoing research and development, which is leading to an increased potential for new and improved treatment options to become available for patients with CNS disorders. There is a growing investment in research and development of gene therapy for CNS disorders, with many biotech and pharmaceutical companies working on developing new gene therapies for these conditions.

For instance, in June 2021, Alcyone Therapeutics announced its launch and receipt of USD 23 million in funding from funds affiliated with RTW Investments, LP. Alcyone is a biotechnology company dedicated to developing precision therapies for severe neurological conditions that impact patients and their families.

Alcyone partnered with the Abigail Wexner Research Institute at Nationwide Children's Hospital to combine its proprietary next-generation CNS delivery platform and product development, manufacturing, and commercialization capabilities with AWRI's four gene therapy technologies and research and early development capabilities.

As more effective treatments become available, patients with CNS may experience better health outcomes and quality of life. This could increase demand for management options and further drive market growth.

What are the Challenges Faced by Gene Therapy in the CNS Disorder Market?

Expensive Cost of Treatment to restrict Market Growth

The market is projected to get significantly affected by challenging factors such as Complexity of delivery, Immune responses, Safety concerns, Regulatory challenges, and Ethical considerations.

Delivering therapeutic genes to the brain is a complex process, as the blood-brain barrier can prevent the delivery of gene therapy vectors to the targeted cells in the brain. The development of efficient delivery systems that can overcome this challenge is crucial for the success of gene therapy in CNS disorders.

Furthermore, gene therapy raises several ethical considerations, including the potential for unintended consequences or the development of genetic enhancements that may have social and ethical implications. Additionally, regulatory hurdles can limit the speed of development and availability of gene therapy treatments for CNS disorders.

Region-Wise Insights

How is the Gene Therapy in CNS Disorder Market Turning Out in the South & East Asian Region?

Increasing Focus on R&D Shaping Landscape for Gene Therapy in CNS Disorders

The gene therapy market for CNS disorders is still in its early stages in the South and East Asian regions, but there is increasing interest in this field and several companies are actively engaged in research and development of gene therapies for CNS disorders in these regions. The South & East Asia region is expected to exhibit the significant growth rate of all regions over the forecast period, with a share of 20% during the forecast period.

The regulatory landscape for gene therapy in the South and East Asian region is evolving, with several countries adopting guidelines for the approval and regulation of gene therapy. For example, the Indian Council of Medical Research (ICMR) recently released guidelines for the ethical, legal and regulatory aspects of gene therapy research and clinical trials in India.

What are the Factors Boosting the Market for Gene Therapy in CNS Disorder in North America?

Increasing Focus on Technological Advancements shaping Landscape for Gene Therapy in CNS Disorder in North America

North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the high prevalence of CNS disorders in North America, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, which has led to a strong demand for new treatments. Additionally, North America has a well-developed healthcare infrastructure, along with a high level of research and development, significant investment, and a supportive regulatory environment.

The United States of America, in particular, has been experiencing an increase in CNS disorders related deaths, which may drive demand for treatment.

The United States of America holds the highest share in the North American market, followed by Canada. Presence of a large number of pharmaceutical companies, which are investing heavily in the development of new, targeted treatments for the condition, and high level of healthcare expenditure leading to a large patient population are some of the factors responsible for the growth of the market in the region.

Category-Wise Insights

By Indication, Which Segment is Likely to Account for a Significant Share?

Alzheimer’s disease to hold a significant share and push market growth

According to Future Market Insights, Alzheimer's disease, in particular, is likely to account for a significant share of the gene therapy in CNS disorders market. This is due to the high prevalence of neurodegenerative disorders.

Alzheimer's disease is a progressive and incurable neurodegenerative disorder that affects millions of people worldwide. It is the most common cause of dementia in the elderly, and the prevalence of the disease is expected to rise in the coming years due to an aging population.

By End User, Which Segment is Likely to Account for a Significant Share?

Hospitals to take the lead and drive market growth

According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the gene therapy in CNS disorder treatment facilitates the growth of this segment.

Majority of the serious diseases involving the nervous system are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.

Market Competition

Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.

• In November 2022, a team of researchers at University College London (UCL) developed a novel gene therapy that offers promise in treating neurological and psychiatric disorders. The therapy targets overactive brain cells that are responsible for causing several brain diseases, including epilepsy, by reducing their excitability. By using DNA sequences that control gene expression, the therapy drives the production of molecules that prevent these overactive cells from firing, thereby curbing epileptic seizures. Notably, the technique selectively alters only overactive cells while sparing normally functioning cells.
• In preclinical studies, the new treatment demonstrated a higher efficacy than previous gene therapies or anti-seizure drugs tested in the same model. The team observed an approximately 80% reduction in spontaneous seizures in epileptic mice treated with the therapy. Furthermore, the researchers believe that this gene therapy has the potential to treat other disorders where some brain cells are overactive, such as Parkinson's disease.

Report Scope

Report Attribute	Details
Market Value in 2023	USD 8.2 billion
Market Value in 2033	USD 113.04 billion
Growth Rate	CAGR of 30% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Type, Indication, End-Users, Region
Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa
Key Countries Profiled	United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled	Voyager Therapeutics; Spark Therapeutics; Novartis AG; Bluebird Bio Inc.; Biogen; Pfizer Inc.; Rapa Therapeutics; BrainStorm Cell Therapeutics; Eli Lily and Company; UniQure Biopharma
Customization	Available Upon Request

Key Segments Profiled in the Gene Therapy in CNS Disorder Industry Survey

Indication:

• Alzheimer's Disease
• Huntington's Disease
• Parkinson's Disease
• Batten Disease

Type:

• Ex Vivo
• In Vivo

End User:

• Hospitals
• Speciality Clinics

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

Frequently Asked Questions

How Big is the Gene Therapy in CNS Disorder Market? 

The market is valued at USD 8.2 billion in 2023. 

Who are the key Market Players? 

Novartis AG, Bluebird Bio Inc., and Biogen are key market players. 

What is the growth forecast for the Market? 

The market is forecast to register a CAGR of 30.0% through 2033. 

What is the North America’s expected share in 2033? 

North America is likely to generate 40% revenue in 2033. 

Which is the top trend in the Market? 

Significant advancements in gene therapy technology is encouraging the market growth.